Skip to main content
. Author manuscript; available in PMC: 2022 Oct 30.
Published in final edited form as: Sci Transl Med. 2022 Mar 16;14(636):eabl9945. doi: 10.1126/scitranslmed.abl9945

Fig. 8. Microglia replacement with CDMCs ameliorates disease progression in Psap-deficient mice.

Fig. 8

(A and B) Motor coordination in the indicated groups was evaluated by the elevated beam test. The beam used was 100 cm in length and 17 mm in width. Number of falling off the beam (A) (df=9, F= 8.377, p<0.0001) and time to cross the beam (B) (df=9, F=18.33, p<0.0001) were measured.

(C to F) Footprints of the indicated groups were evaluated for stride length of left forelimb (C) (df=9, F= 8.467, p<0.0001), right forelimb (D) (df=9, F= 12.47, p<0.0001), left hindlimb (E) (df=9, F= 6.486, p<0.0001), and right hindlimb (F) (df=9, F= 6.832, p<0.0001).

(G) Locomotor behavior was assessed by the open field test in the indicated groups. Plot demonstrates area measure, a metric of the number of sharp turns instead of straight-line runs during a 20-minute open field trial (df=8, F= 9.59, p<0.0001).

All behavior assays were analyzed statistically by ANOVA. Mean ± SEM, *p<0.05, **p<0.005, ***p<0.0005, ****p<0.0001. PSAPHigh (n=6), PSAPLow(n=7), PSAPLow→PSAPLow(n=9), PSAPHigh→PSAPLow (n=9), PSAPHigh→PSAPHigh (n=9)

(H) Lifespan of PSAPLow (green, n=10), PSAPLow→PSAPLow (black, n=9), PSAPHigh→PSAPLow (red, n=7), and PSAPHigh→PSAPHigh, (blue, n=8). (***p< 0.001, *p< 0.05, ns: not significant, vs PSAPLow mice, Logrank. Chi square= 35.9, df=3, p<0.0001).